Similar articles

• Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.

  Bhardwaj A, Rehman SU, Mohammed AA, Gaggin HK, Barajas L, Barajas J, Moore SA, Sullivan D, Januzzi JL. Bhardwaj A, et al. Am Heart J. 2012 Nov;164(5):793-799.e1. doi: 10.1016/j.ahj.2012.08.015. Am Heart J. 2012. PMID: 23137512 Clinical Trial.
• N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

  Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. Lainchbury JG, et al. J Am Coll Cardiol. 2009 Dec 29;55(1):53-60. doi: 10.1016/j.jacc.2009.02.095. J Am Coll Cardiol. 2009. PMID: 20117364 Clinical Trial.
• Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.

  Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr. Bhardwaj A, et al. Am Heart J. 2010 Apr;159(4):532-538.e1. doi: 10.1016/j.ahj.2010.01.005. Am Heart J. 2010. PMID: 20362709 Clinical Trial.
• Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.

  Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Wessler BS, et al. Circ Heart Fail. 2011 Sep;4(5):578-88. doi: 10.1161/CIRCHEARTFAILURE.111.961573. Epub 2011 Jun 24. Circ Heart Fail. 2011. PMID: 21705485 Review.
• Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure.

  Masson S, Latini R. Masson S, et al. Am J Cardiol. 2008 Feb 4;101(3A):56-60. doi: 10.1016/j.amjcard.2007.11.024. Am J Cardiol. 2008. PMID: 18243860 Review.